瑞科生物－B(02179.HK) 公布，董事会已于5月21日(昨日)审议批准，拟将公司约1.42亿股未上市股份转换为公司H股。在取得所有相关备案及批准及符合所有适用的法律、规则及法规后，有关未上市股份将被转换为H股，公司将向联交所申请该等H股于主板上市及买卖。(ha/a)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.